http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#Head http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#provenance http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#pubinfo http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion http://purl.obolibrary.org/obo/MONDO_0005052 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0005052 http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://go.drugbank.com/drugs/DB00904 http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association http://www.w3.org/2000/01/rdf-schema#label Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment. http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association https://w3id.org/biolink/vocab/publications https://pubmed.ncbi.nlm.nih.gov/28276811/ http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/OffLabelIndication http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort http://www.w3.org/2000/01/rdf-schema#label Adults http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#cohort https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Cohort https://go.drugbank.com/drugs/DB00904 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#provenance http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#pubinfo http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig http://purl.org/nanopub/x/hasSignature L7B3xksOrZtTwhr+neU351oQTkKxdQ8d6a7uB9vlY5FxCWACAqmvtx4gDCK8OTP1qgKrtMHNis/p13yNWgfZjSb2q7c9F/CjxDznQctKGkNa3ny8089AEfMTBl7XUhx/OwnzPrsPBm9ZVzyQZDuz8mJZ+eLSRgXl8+tIIr2JWRc= http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://purl.org/dc/terms/created 2021-05-28T17:40:31.342+02:00 http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M http://purl.org/dc/terms/creator https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAytl9AFqJs8aXvS34NgLmtChr5_wZX4Cg1uGI9ntzZ7M https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs